{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:41:09Z","timestamp":1792449669610,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007547","name":"Fourth Military Medical University","doi-asserted-by":"publisher","award":["2021JSTS07"],"award-info":[{"award-number":["2021JSTS07"]}],"id":[{"id":"10.13039\/501100007547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373733"],"award-info":[{"award-number":["82373733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018611","name":"International Science and Technology Cooperation Program of Shanxi Province","doi-asserted-by":"publisher","award":["2024GH-YBXM-18"],"award-info":[{"award-number":["2024GH-YBXM-18"]}],"id":[{"id":"10.13039\/501100018611","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bmcl.2024.130082","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:11:10Z","timestamp":1734653470000},"page":"130082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia"],"prefix":"10.1016","volume":"117","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyou","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2383-2673","authenticated-orcid":false,"given":"Shengzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.130082_b0005","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat Rev Disease Prim"},{"key":"10.1016\/j.bmcl.2024.130082_b0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2024.130082_b0015","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol Rev"},{"key":"10.1016\/j.bmcl.2024.130082_b0020","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3390\/jcm12206429","article-title":"A review of FLT3 kinase inhibitors in AML","volume":"12","author":"Negotei","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.bmcl.2024.130082_b0025","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","article-title":"Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients","volume":"28","author":"Kihara","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.bmcl.2024.130082_b0030","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130082_b0035","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130082_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmcl.2024.130082_b0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms Underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmcl.2024.130082_b0050","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Therapeut Adv Hematol"},{"key":"10.1016\/j.bmcl.2024.130082_b0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2016.06.002","article-title":"FLT3 inhibitors for treating acute myeloid leukemia","volume":"16","author":"Hassanein","year":"2016","journal-title":"Clin Lymphoma Myelom Leukem"},{"key":"10.1016\/j.bmcl.2024.130082_b0060","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2024.130082_b0065","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.hoc.2017.04.005","article-title":"Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment","volume":"31","author":"Ghiaur","year":"2017","journal-title":"Hematol\/Oncol Clin North Am"},{"key":"10.1016\/j.bmcl.2024.130082_b0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nature11016","article-title":"Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia","volume":"485","author":"Smith","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.130082_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8828","article-title":"Overcoming adaptive therapy resistance in AML by targeting immune response pathways","volume":"11","author":"Melgar","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2024.130082_b0080","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N\u2032-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-Like Tyrosine Kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130082_b0085","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.3390\/cancers13246181","article-title":"Efficacy and synergy of small molecule inhibitors targeting FLT3-ITD(+) acute myeloid leukemia","volume":"13","author":"Bregante","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bmcl.2024.130082_b0090","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.bmcl.2024.130082_b0095","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget."},{"key":"10.1016\/j.bmcl.2024.130082_b0100","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bmcl.2024.130082_b0105","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.bmcl.2024.130082_b0110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41420-023-01528-5","article-title":"NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Chen","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bmcl.2024.130082_b0115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.cdd.4401231","article-title":"Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis","volume":"10","author":"Gottlieb","year":"2003","journal-title":"Cell Death Different"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:24:19Z","timestamp":1737321859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24004840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"alternative-id":["S0960894X24004840"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130082","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 3-amide-pyrimidine-based derivatives as potential fms-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130082"}}